PTC Therapeutics Announces Phase 3 APHENITY Trial Results: Over 97% Of Subjects Participating In The Phe Tolerance Protocol Of The APHENITY Open-Label Extension Study Demonstrate The Ability To Liberalize Their Diet While On Sepiapterin Treatment, With A